Clinical Trial Update: Ganciclovir Plus Arginine Butyrate in Treating Patients With Cancer or Lymphoproliferative Disorders Associated With the Epstein Barr Virus [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating ganciclovir plus arginine butyrate in EBV-associated cancers; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Lymphoma
• Small Intestine Cancer

Drugs mentioned

• Arginine butyrate (arginine butyrate)
• GANCICLOVIR (GANCICLOVIR SODIUM)

Snippet

Sponsor: Boston Medical Center | Conditions: Leukemia, Lymphoma | Phase 1 | Status: COMPLETED